Lifeboat Foundation

We’re only starting in this space.

Synthetic Biology (SynBio) includes a large field of applications. Within this area biochemists combine engineering concepts and techniques with biology to design new genes that produce a specific protein. When this protein is an enzyme, bacteria and yeast in which such a gene is implanted can produce specific chemicals through a fermentation process. A large and growing number of businesses is active in this field. This became apparent once again at the EFIB-conference in Glasgow, last October. The workshop was chaired by John Cumbers, founder of the American SynBioBeta, an internet-site dedicated to sharing information and news on synthetic biology.

JBEI researchers develop efficient and affordable method for plant DNA assembly.

Researchers at the U.S. Department of Energy (DOE)’s Joint BioEnergy Institute (JBEI) in collaboration with Berkeley Lab’s Environmental Genomics & Systems Biology Division and the DOE Joint Genome Institute developed a versatile system (named jStack) which utilizes yeast homologous recombination to efficiently assemble DNA into plant transformation vectors. The new approach will impact plant engineering for the bioenergy, agricultural and pharmaceutical industries.

Although synthetic biology has provided solutions to many societal challenges, little research has been devoted to advancing synthetic biology in plants. Microbes, such as yeast and Escherichia coli (E. coli), have received much of the attention in developing synthetic biology tools due to their fast generation time and the ease of working with these organisms in laboratories. A shortage of characterized DNA parts, along with the difficulty of efficiently assembling multiple and large fragments of DNA into plant transformation vectors, has limited progress in studying and engineering plants to the same degree as their microbial counterparts.

You get out what you put in.

You are what you eat, the old saying goes, but why is that so? Researchers have known for some time that diet affects the balance of microbes in our bodies, but how that translates into an effect on the host has not been understood. Now, research in mice is showing that microbes communicate with their hosts by sending out metabolites that act on histones—thus influencing gene transcription not only in the colon but also in tissues in other parts of the body. The findings publish November 23 in Molecular Cell.

“This is the first of what we hope is a long, fruitful set of studies to understand the connection between the microbiome in the gut and its influence on host health,” says John Denu, a professor of biomolecular chemistry at the University of Wisconsin, Madison, and one of the study’s senior authors. “We wanted to look at whether the gut microbiota affect epigenetic programming in a variety of different tissues in the host.” These tissues were in the proximal colon, the liver, and fat tissue.

Continue reading “Changes in the diet affect epigenetics via the microbiota” »

Destroying and replacing the immune system is one of the approaches to treat the aging process.

Fightaging! provides some commentary about the immune system in relation to aging. Addressing the decline of the immune system is one of the approaches SRF is interested in and is a cornerstone of rejuvenation biotechnology.

“Understanding exactly how aging progressively harms the intricate choreography of the immune response is a massive project, and nowhere near completion. It is possible to judge how far along researchers are in this work by the side effect of the quality of therapies for autoimmune disease, which are malfunctions in immune configuration, and largely incurable at the present time. From a practical point of view, and as mentioned above, the best prospects for effective treatments in the near future involve destroying and recreating the immune system. That works around our comparative ignorance by removing all of the problems that researchers don’t understand in addition to ones that they do.”

Continue reading “Some Adaptive Immune Cells Become More Innate-Like in the Aged Immune System” »

This gives a very simple summary of the process of drug development.

The development process from Pre-Clinical testing to an approved product we can use is a long one. A global average of 17 years with the US being 12 years is the historical norm for new drugs and therapies to be developed.

#aging #crowdfundthecure

Continue reading “The road is long but we can get there” »

A laboratory in Lanarkshire has started harvesting stem cells from children’s teeth.

It’s hoped the cells can be used in a cure if the children develop a disease later in life.

The American company BioEden will cryogenically store the cells in return for a monthly fee.

Continue reading “Commercial harvesting of stem cells under way” »

Happy Thanksgiving! This year during your holiday meal, share what you are thankful for and think about how to pay it forward on #GivingTuesday.

We are working hard to treat age-related diseases so that we all get to enjoy more wonderful days together like this. We need your help to do it.

#sens

Continue reading “Happy Thanksgiving from SENS Research :D” »

Speculation about what order rejuvenation biotechnologies will arrive.

The first rejuvenation therapies to work well enough to merit the name will be based on the SENS vision: that aging is at root caused by a few classes of accumulated cell and tissue damage, and biotechnologies that either repair that damage or render it irrelevant will as a result produce rejuvenation. Until very recently, no medical technology could achieve this goal, and few research groups were even aiming for that outcome. We are in the midst of a grand transition, however, in which the research and development community is finally turning its attention to the causes of aging, understanding that this is the only way to effectively treat and cure age-related disease. Age-related diseases are age-related precisely because they are caused by the same processes of damage that cause aging: the only distinctions between aging and disease are the names given to various collections of symptoms. All of frailty, disease, weakness, pain, and suffering in aging is the result of accumulated damage at the level of cells and protein machinery inside those cells. Once the medical community becomes firmly set on the goal of repairing that damage, we’ll be well on the way to controlling and managing aging as a chronic condition — preventing it from causing harm to the patient by periodically repairing and removing its causes before they rise to the level of producing symptoms and dysfunction. The therapies of the future will be very different from the therapies of the past.

The full rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. In this post, I’ll take a look at the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development. This is an update to a similar post written four years ago, now become somewhat dated given recent advances in the field. Circumstances change, and considerable progress has been made in some lines of research and development.

Continue reading “Predicting the Order of Arrival of the First Rejuvenation Therapies” »

Our brains have a basic algorithm that enables us to not just recognize a traditional Thanksgiving meal, but the intelligence to ponder the broader implications of a bountiful harvest as well as good family and friends.

“A relatively simple mathematical logic underlies our complex brain computations,” said Dr. Joe Z. Tsien, neuroscientist at the Medical College of Georgia at Augusta University, co-director of the Augusta University Brain and Behavior Discovery Institute and Georgia Research Alliance Eminent Scholar in Cognitive and Systems Neurobiology.